J&J seeks dismissal of US case claiming kickbacks to Omnicare
This article was originally published in Scrip
Executive Summary
Johnson & Johnson is aggressively fighting claims in a whistleblower lawsuit, joined by the US Department of Justice and several states, which charges that J&J paid tens of millions of dollars in kickbacks between 1999 and 2004 to induce Omnicare, a provider of pharmacy services, to boost use of J&J medicines such as the antipsychotic Risperdal (risperidone) to its nursing home clients. J&J argues that the alleged kickbacks were standard, legal contracting arrangements pertaining to increased rebates for obtaining market share, and are allowable under federal law.
You may also be interested in...
ChemoCentryx cuts price to get $45M IPO away
ChemoCentryx has successfully completed its initial public offering on Nasdaq, raising $45 million to help support its multiple R&D programmes. It sold 4.5 million shares at $10, a somewhat less ambitious debut than it had originally planned in January when it wanted to sell four million shares at $14-$16. The reduced offer is a sign of the challenging nature of the IPO market, but ChemoCentryx's assessment of its own worth was at least closer to the market’s assessment that Cempra which got its IPO away on 6 February at valuation that was less than two-thirds of that implied by its initial prospectus (scripintelligence.com, 7 February 2012).
Ampio raises $16.9M as it advances PhIII premature ejaculation drug
Ampio Pharmaceuticals, a development-stage company, initially raised $15 million which was boosted to $16.9 million by the exercise of overallotments by brokers. The shares were offered at $3.25, an 8.5% discount to the closing price of $3.66 on 12 July. The market pushed them down slightly further to 3.21 on 13 July.
Money talks: Verastem leverages IPO to build cancer stem cell pipeline
Verastem, a cancer stem cells startup, has moved quickly to build its pipeline just five months after an initial public offering. Management at the Cambridge, Massachusetts firm believes that recent moves have accelerated Verastem's clinical development plans by a year.